

Violeta Sanchez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/784754/publications.pdf>

Version: 2024-02-01

26
papers

2,091
citations

430874

18
h-index

642732

23
g-index

26
all docs

26
docs citations

26
times ranked

4511
citing authors

#	ARTICLE	IF	CITATIONS
1	MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation. <i>Cell Metabolism</i> , 2017, 26, 633-647.e7.	16.2	449
2	Molecular Profiling of the Residual Disease of Triple-Negative Breast Cancers after Neoadjuvant Chemotherapy Identifies Actionable Therapeutic Targets. <i>Cancer Discovery</i> , 2014, 4, 232-245.	9.4	413
3	DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer. <i>Nature Communications</i> , 2018, 9, 248.	12.8	181
4	Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer. <i>Cancer Research</i> , 2017, 77, 2488-2499.	0.9	178
5	A case report of clonal EBV-like memory CD4+ T cell activation in fatal checkpoint inhibitor-induced encephalitis. <i>Nature Medicine</i> , 2019, 25, 1243-1250.	30.7	133
6	Genomic profiling of ER ⁺ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	91
7	Extracellular Matrix/Integrin Signaling Promotes Resistance to Combined Inhibition of HER2 and PI3K in HER2+ Breast Cancer. <i>Cancer Research</i> , 2017, 77, 3280-3292.	0.9	76
8	Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i> -Amplified Breast Cancers. <i>Cancer Research</i> , 2016, 76, 4752-4764.	0.9	71
9	Treatment-Induced Tumor Cell Apoptosis and Secondary Necrosis Drive Tumor Progression in the Residual Tumor Microenvironment through MerTK and IDO1. <i>Cancer Research</i> , 2019, 79, 171-182.	0.9	57
10	Two distinct mTORC2-dependent pathways converge on Rac1 to drive breast cancer metastasis. <i>Breast Cancer Research</i> , 2017, 19, 74.	5.0	55
11	Selective mTORC2 Inhibitor Therapeutically Blocks Breast Cancer Cell Growth and Survival. <i>Cancer Research</i> , 2018, 78, 1845-1858.	0.9	54
12	Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2. <i>OncotImmunology</i> , 2018, 7, e1438106.	4.6	54
13	Targeting MYCN-expressing triple-negative breast cancer with BET and MEK inhibitors. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	46
14	Key Survival Factor, Mcl-1, Correlates with Sensitivity to Combined Bcl-2/Bcl-xL Blockade. <i>Molecular Cancer Research</i> , 2017, 15, 259-268.	3.4	40
15	Tumor-Specific Major Histocompatibility-II Expression Predicts Benefit to Anti-PD-1/L1 Therapy in Patients With HER2-Negative Primary Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 5299-5306.	7.0	39
16	Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 5668-5681.	7.0	37
17	Quantitative [18F]FMISO PET Imaging Shows Reduction of Hypoxia Following Trastuzumab in a Murine Model of HER2+ Breast Cancer. <i>Molecular Imaging and Biology</i> , 2017, 19, 130-137.	2.6	24
18	ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation. <i>Breast Cancer Research</i> , 2017, 19, 105.	5.0	23

#	ARTICLE	IF	CITATIONS
19	Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers. <i>Oncotarget</i> , 2019, 10, 5389-5402.	1.8	18
20	Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers. <i>Cell Death and Disease</i> , 2018, 9, 21.	6.3	16
21	Tissue-specific expression of p73 and p63 isoforms in human tissues. <i>Cell Death and Disease</i> , 2021, 12, 745.	6.3	13
22	ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma. <i>Oncotarget</i> , 2015, 6, 22348-22360.	1.8	12
23	Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	11
24	Abstract PS17-14: Evaluating the efficacy of immunotherapy in triple negative breast cancer. , 2021, , .		0
25	Abstract PS4-19: Evaluation of tumor-specific MHC-II expression as a biomarker. , 2021, , .		0
26	245...Host myeloid response to tumor and immunotherapy is associated with heterogeneity in outcomes to anti-PDL1. , 2021, 9, A264-A264.		0